SPRO (Spero Therapeutics, Inc. Common Stock) Stock Analysis - AI Report
Spero Therapeutics, Inc. Common Stock (SPRO) is a publicly traded Healthcare sector company. As of May 21, 2026, SPRO trades at $2.60 with a market cap of $149.39M and a P/E ratio of 0.00. SPRO moved +1.16% today. Year to date, SPRO is +8.23%; over the trailing twelve months it is +286.65%. Its 52-week range spans $0.51 to $3.22. Rallies surfaces SPRO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What is the AI research view on SPRO?
Rallies AI research for SPRO combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
Rajavelu Esther sold 25.24K (~$63.35K) on May 4, 2026.
Rajavelu Esther sold 37.10K (~$87.56K) on Feb 6, 2026.
Rajavelu Esther sold 50.82K (~$119.93K) on Feb 6, 2026.
SPRO Analyst Consensus
SPRO analyst coverage data. Average price target: $0.00.
Common questions about SPRO
What is the AI research view on SPRO?
Rallies AI research for SPRO combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
What data powers the Rallies AI report for SPRO?
Rallies AI research for SPRO combines live market data, financials, news, analyst context, hedge fund ownership, politician disclosures, insider activity, and risk factors.
Is SPRO research on Rallies investment advice?
No. Rallies provides research, data, and educational context for SPRO. It does not provide personalized investment advice.